Price Discrimination Essay

857 Words2 Pages

TOPIC: PRICE DISCRIMINATION http://www.hcs.harvard.edu/hghr/online/price-discrimination-method/ In a market there can be many types of pricing strategies. Some of these include: average pricing, marginal cost pricing, penetration pricing, skimming price, price discrimination, cost plus pricing, kinked price among others. Most of these strategies are based on the aim of profit maximisation. The pricing strategy differs under the different market structures like perfect competition, monopolistic competition, oligopoly and monopoly. Price discrimination is a common pricing strategy used by monopolist. It involves charging consumers different prices for the same good. It is only possible with a monopolist, as we need a single seller to sell to …show more content…

Rates are cheaper at night compared to day time. This is effective as consumers cant store electricity in the nite when it is cheaper and use it in the morning. The costs of storing are greater than the price differential, which makes it irrational to store at night.

Some phone companies charge on the basis of usage. The first 100 minutes of talk time is more costly. The next 200 minutes are cheaper. This means that the same consumer is charged a different price per minute depending on total usage. This is often done to encourage greater use as the sunk costs and fixed of providing a phone connection are high. The only way to recover costs is to earn higher revenues through greater usage of talk time
The essential requirement for effective price discrimination is …show more content…

We can look at this from 2 perspectives. One is the pharma company that invests billions into development of a drug that takes many long years to come into the market. Once approved the company wants to recover its costs of research and development within the patented years. ‘A recent study conducted by the Centre for Medicine Research (CMR) on 16 pharmaceutical companies that account for 60% of the world’s research and development spending estimates that Phase II trial success rates have fallen by 10 percentage points to just 18% from 2006 to 2009. Furthermore, only half of drugs make it through Phase III trials. All this is to say that drug development is a high-risk, high-reward

Open Document